Cargando…
Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells
In 2006, the induced pluripotent stem cell (iPSC) was presented to the world, paving the way for the development of a magnitude of novel therapeutic alternatives, addressing a diverse range of diseases. However, despite the immense cell therapy potential, relatively few clinical trials evaluating iP...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445612/ https://www.ncbi.nlm.nih.gov/pubmed/34532844 http://dx.doi.org/10.1007/s12015-021-10262-3 |
_version_ | 1784568686155137024 |
---|---|
author | Kim, Jennifer Yejean Nam, Yoojun Rim, Yeri Alice Ju, Ji Hyeon |
author_facet | Kim, Jennifer Yejean Nam, Yoojun Rim, Yeri Alice Ju, Ji Hyeon |
author_sort | Kim, Jennifer Yejean |
collection | PubMed |
description | In 2006, the induced pluripotent stem cell (iPSC) was presented to the world, paving the way for the development of a magnitude of novel therapeutic alternatives, addressing a diverse range of diseases. However, despite the immense cell therapy potential, relatively few clinical trials evaluating iPSC-technology have actually translated into interventional, clinically applied treatment regimens. Herein, our aim was to determine trends in globally conducted clinical trials involving iPSCs. Data were derived both from well-known registries recording clinical trials from across the globe, and databases from individual countries. Comparisons were firstly drawn between observational and interventional studies before the latter was further analyzed in terms of therapeutic and nontherapeutic trials. Our main observations included global distribution, purpose, target size, and types of disorder relevant to evaluated trials. In terms of nontherapeutic trials, the USA conducted the majority, a large average number of participants—187—was included in the trials, and studies on circulatory system disorders comprised a slightly higher proportion of total studies. Conversely, Japan was the frontrunner in terms of conducting therapeutic trials, and the average number of participants was much lower, at roughly 29. Disorders of the circulatory, as well as nervous and visual systems, were all studied in equal measure. This review highlights the impact that iPSC-based cell therapies can have, should development thereof gain more traction. We lastly considered a few companies that are actively utilizing iPSCs in the development of therapies for various diseases, for whom the global trends in clinical trials could become increasingly important. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12015-021-10262-3. |
format | Online Article Text |
id | pubmed-8445612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-84456122021-09-17 Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells Kim, Jennifer Yejean Nam, Yoojun Rim, Yeri Alice Ju, Ji Hyeon Stem Cell Rev Rep Article In 2006, the induced pluripotent stem cell (iPSC) was presented to the world, paving the way for the development of a magnitude of novel therapeutic alternatives, addressing a diverse range of diseases. However, despite the immense cell therapy potential, relatively few clinical trials evaluating iPSC-technology have actually translated into interventional, clinically applied treatment regimens. Herein, our aim was to determine trends in globally conducted clinical trials involving iPSCs. Data were derived both from well-known registries recording clinical trials from across the globe, and databases from individual countries. Comparisons were firstly drawn between observational and interventional studies before the latter was further analyzed in terms of therapeutic and nontherapeutic trials. Our main observations included global distribution, purpose, target size, and types of disorder relevant to evaluated trials. In terms of nontherapeutic trials, the USA conducted the majority, a large average number of participants—187—was included in the trials, and studies on circulatory system disorders comprised a slightly higher proportion of total studies. Conversely, Japan was the frontrunner in terms of conducting therapeutic trials, and the average number of participants was much lower, at roughly 29. Disorders of the circulatory, as well as nervous and visual systems, were all studied in equal measure. This review highlights the impact that iPSC-based cell therapies can have, should development thereof gain more traction. We lastly considered a few companies that are actively utilizing iPSCs in the development of therapies for various diseases, for whom the global trends in clinical trials could become increasingly important. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12015-021-10262-3. Springer US 2021-09-16 2022 /pmc/articles/PMC8445612/ /pubmed/34532844 http://dx.doi.org/10.1007/s12015-021-10262-3 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Kim, Jennifer Yejean Nam, Yoojun Rim, Yeri Alice Ju, Ji Hyeon Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells |
title | Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells |
title_full | Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells |
title_fullStr | Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells |
title_full_unstemmed | Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells |
title_short | Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells |
title_sort | review of the current trends in clinical trials involving induced pluripotent stem cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445612/ https://www.ncbi.nlm.nih.gov/pubmed/34532844 http://dx.doi.org/10.1007/s12015-021-10262-3 |
work_keys_str_mv | AT kimjenniferyejean reviewofthecurrenttrendsinclinicaltrialsinvolvinginducedpluripotentstemcells AT namyoojun reviewofthecurrenttrendsinclinicaltrialsinvolvinginducedpluripotentstemcells AT rimyerialice reviewofthecurrenttrendsinclinicaltrialsinvolvinginducedpluripotentstemcells AT jujihyeon reviewofthecurrenttrendsinclinicaltrialsinvolvinginducedpluripotentstemcells |